Rett Syndrome Financial Planning: Daybue Costs, SSDI Fast-Track, and SNT Strategy

Rett syndrome is almost exclusively a condition of girls and women. A daughter appears to develop normally through the first six to eighteen months of life, then enters a period of regression — losing purposeful hand use, losing language, developing repetitive hand movements and breathing irregularities — that transforms both her life and her family's financial planning needs. The central financial challenge has two parts: first, ensuring that disability benefits (SSI, Medicaid, HCBS waiver services) are in place and maintained throughout her life, including through the critical Medicaid dependency created by Daybue, the first FDA-approved treatment for Rett syndrome; and second, funding a Special Needs Trust that provides lifetime supplemental support without ever touching the means-tested benefits her care depends on. This guide covers both.

Who this affects: Rett syndrome prevalence and profile

Rett syndrome affects approximately 1 in 10,000 to 15,000 female live births, with an estimated 15,000 to 20,000 girls and women living with the condition in the United States.¹ Rett is almost exclusively a condition of females. It is caused by mutations in the MECP2 gene on the X chromosome; because males typically carry only one X chromosome, MECP2 mutations in males are usually lethal before birth or shortly after. The rare males with Rett syndrome (caused by Klinefelter syndrome or somatic mosaicism) typically have severe or neonatal-lethal presentations.

The condition is de novo in the vast majority of cases — meaning the MECP2 mutation occurs spontaneously, is not inherited from parents, and does not follow a predictable family inheritance pattern. Rett families typically receive the diagnosis without warning, often after watching their daughter develop normally through infancy and then begin to regress.

The four stages of Rett syndrome: financial planning by phase

Rett syndrome follows a recognized four-stage clinical course. Each stage has distinct financial planning implications.

Stage I: Early onset stagnation (approximately 6–18 months)

Development slows or plateaus, but regression has not yet begun. This stage can be subtle and may not be immediately recognized as Rett syndrome. Most diagnoses occur during or after Stage II. Financial planning action in Stage I: Begin the MECP2 molecular genetic test if Rett is suspected — the test result is the primary documentation for SSA's Compassionate Allowance fast-track. If diagnosis is confirmed during Stage I, apply for SSI immediately.

Stage II: Rapid deterioration (approximately ages 1–4)

The defining regression period. Purposeful hand use is lost and replaced by characteristic repetitive hand-wringing, hand-washing, or hand-squeezing movements. Language regresses or disappears. Breathing irregularities emerge — hyperventilation, breath-holding, and air swallowing that can look alarming and require family education to manage. Seizures begin in approximately 80–90% of individuals during this period.¹ Gait abnormalities and anxiety behaviors appear. Financial planning urgency in Stage II: SSI application is the immediate priority. HCBS developmental disability waiver application follows — waitlists run 5–15 years, and applying now means a slot may be available at age 21 when school-based IDEA services end. Medicaid established via SSI enables access to Daybue if the treating physician prescribes it.

Stage III: Plateau (approximately ages 2–10 and through adulthood)

For many girls and women, Stage II regression stabilizes into a period of relative plateau or modest improvement. Hand use does not return fully, but some women show improved communication, increased alertness, and better seizure control. Many women with Rett live in Stage III for decades. Financial planning in Stage III: This is the primary period for building the SNT, securing life insurance on parents, and ensuring all beneficiary designations route through the SNT rather than to the daughter personally. HCBS waiver services begin adding residential and day programming support.

Stage IV: Late motor deterioration (from approximately age 10 onward, in some)

A subset of women with Rett experience progressive loss of mobility — scoliosis progression, muscle weakness, and reduced or lost ambulatory ability. Communication improvements from Stage III often persist. Financial planning in Stage IV: Scoliosis surgical reserves, wheelchair seating systems, accessible housing modifications, and intensive personal care needs enter the SNT cost model. Parents' own capacity to provide hands-on care declines with age, making professional residential care planning more urgent.

SSI and SSDI: early application and the Compassionate Allowance fast-track

SSI (Supplemental Security Income) is the correct starting point for most Rett families. Unlike SSDI, which requires a work history, SSI requires only demonstrated disability and financial need. For a child diagnosed with Rett syndrome, SSI is typically accessible as soon as the diagnosis is confirmed — often by age 2 or 3 during Stage II regression.

Compassionate Allowances: fast-track for Rett syndrome

Rett syndrome is included on SSA's Compassionate Allowances (CAL) program — a designated list of conditions that are inherently and severely disabling.² CAL status means SSA identifies these cases early in the processing queue and routes them for expedited review. For Rett syndrome applications with adequate medical documentation — specifically, the results of MECP2 molecular genetic testing confirming the mutation — a disability determination can be issued in approximately 10 days, compared to the standard 3–6 month process for most disability claims.

Required documentation for a Rett CAL application:

• MECP2 molecular genetic test results confirming the mutation (identifies the cause of Rett in approximately 80–95% of classic cases)
• Clinical documentation of Rett syndrome staging — loss of purposeful hand use, repetitive hand movements, breathing irregularities
• Physician records from the treating neurologist or developmental pediatrician

Applications without genetic confirmation may still qualify through standard processing timelines, but the genetic test is the fastest path to CAL fast-track approval. Apply with the test results in hand.

SSI mechanics: the $2,000 resource limit and Medicaid linkage

SSI provides a federal benefit of up to $994 per month in 2026 (the Federal Benefit Rate).³ The resource limit is $2,000 in countable assets — meaning your daughter cannot own more than $2,000 in countable resources (bank accounts, investments) and remain SSI-eligible. This limit is why properly structured gifts and inheritances are so important: an unstructured gift that puts more than $2,000 in her name ends SSI and Medicaid. The correct vehicle for all family gifts and bequests is the Special Needs Trust — not her personal accounts.

In most states, SSI eligibility automatically triggers Medicaid eligibility. This Medicaid linkage is the financial cornerstone of Rett syndrome planning because Medicaid is the payer for Daybue — and maintaining Medicaid intact throughout her life is the single most consequential financial goal for families whose daughter is on or expects to start Daybue therapy.

Disabled Adult Child (DAC) benefits at parent retirement or death

When a parent retires, becomes disabled, or dies, a daughter with Rett syndrome may qualify for Disabled Adult Child (DAC) benefits on the parent's Social Security earnings record — up to 50% of the parent's primary insurance amount while the parent is living (or 75% after death). DAC benefits can significantly exceed SSI's $994/month FBR depending on the parent's earnings record, and DAC beneficiaries eventually qualify for Medicare after 24 months of entitlement. The SSI/Medicaid coordination with DAC benefits requires careful planning; see the Disabled Adult Child Social Security guide for the full analysis.

Daybue (trofinetide): the first Rett treatment and the Medicaid imperative

In March 2023, the FDA approved trofinetide (brand name Daybue) for the treatment of Rett syndrome in adults and children aged 2 years and older — the first treatment ever approved specifically for Rett syndrome.⁴ For families whose daughters are candidates for Daybue, this development transforms the financial planning landscape in one critical way: Medicaid must remain intact.

What Daybue costs

Daybue's list price at launch was approximately $375,000 per year. Because dosing is weight-based and administered twice daily, actual annual costs range from approximately $427,000 to $1.335 million per year depending on patient weight.⁴ This price range exceeds what any family can fund privately for more than a few years without exhausting substantial inherited wealth — which is exactly why Medicaid coverage is essential.

In early 2026, FDA approved Daybue Stix, a new powder formulation for oral suspension, which launched on a limited basis in Q1 2026 and became more broadly available in Q2 2026. The original liquid solution formulation remains available alongside the new formulation. Families currently on Daybue should confirm their pharmacist has the formulation their daughter tolerates — the two formulations are therapeutically equivalent but differ in preparation and administration.

Why Medicaid must stay intact

Daybue is covered by Medicaid in most states as an FDA-approved treatment for an approved indication. Private insurance also covers it in many cases, but coverage gaps, prior authorization requirements, and formulary changes create discontinuity risk that well-managed Medicaid eligibility avoids. For a family whose daughter is on Daybue — or who expects to start it — Medicaid continuity is not a secondary consideration; it is the primary financial planning goal.

The two most common ways Rett families inadvertently destroy Medicaid:

• A direct gift or bequest in the daughter's own name that pushes her countable assets above the $2,000 SSI resource limit, ending SSI and Medicaid. A grandparent who leaves $50,000 directly to a grandchild with Rett syndrome can terminate Medicaid coverage for a $400,000-per-year medication — a cost that quickly exceeds any inheritance received.
• A beneficiary designation on a retirement account or life insurance policy naming the daughter directly. An inherited IRA or 401(k) paid to an SSI recipient counts as income in the month received and as a resource thereafter, destroying SSI and Medicaid. Every beneficiary designation in the family's estate should route assets to the SNT, not to the daughter personally. See the Retirement Accounts and Special Needs guide.

Section 1619(b) Medicaid protection

Section 1619(b) of the Social Security Act protects Medicaid eligibility even when earned income exceeds the SGA threshold ($1,690/month in 2026), as long as the individual has a disabling condition and needs Medicaid to work.³ Most women with Rett will not be in work situations where 1619(b) is relevant, but for those in higher-functioning supported employment programs, this protection ensures that limited earned income does not trigger Medicaid loss and interrupt access to Daybue.

Gene therapy pipeline: what families should know for planning purposes

MECP2 gene therapy for Rett syndrome represents the most consequential potential development in Rett medical care — and a financial planning question families are increasingly asking about. Two programs are furthest in clinical development as of 2026.

TSHA-102 (Taysha Gene Therapies)

Taysha's TSHA-102 is a one-time intrathecally delivered gene therapy using an AAV9 vector with a novel miRNA-Responsive Auto-Regulatory Element (miRARE) technology designed to deliver a functional MECP2 gene to cells in the central nervous system while preventing overexpression — a key safety concern, since excess MECP2 protein is itself toxic.⁵ TSHA-102 received FDA Breakthrough Therapy designation. As of 2026, Taysha is completing dosing across Phase 1/2 REVEAL (older patients) and ASPIRE (ages 2 to under 4) trials, with a Biologics License Application (BLA) submission planned after adequate safety data is accumulated. No FDA approval has been issued as of this writing.

NGN-401 (Neurogene)

Neurogene's NGN-401 uses a different gene regulation approach (EXACT™ technology) to deliver full-length MECP2 under controlled expression. NGN-401 is also in Phase 1/2 clinical evaluation. Neither NGN-401 nor TSHA-102 is FDA-approved as of 2026; both are investigational.⁵

Financial planning implications of the gene therapy pipeline

Gene therapies that have received FDA approval in recent years have launched at prices of $2 million to $3.5 million for one-time administration. If TSHA-102 or NGN-401 receives approval, a similar price range is plausible. For families planning a Special Needs Trust today, the practical guidance is:

• Do not hollow out the SNT in anticipation of gene therapy. A functional cure for Rett syndrome is not guaranteed, and Daybue's $400K–$1.3M/yr ongoing cost means supplemental medical expenses will continue regardless of whether gene therapy is eventually approved.
• Maintain Medicaid eligibility. Medicaid has been the primary payer for approved gene therapies in comparable conditions. Preserving Medicaid eligibility is the most important step a family can take to ensure access to gene therapy if and when it is approved for Rett syndrome.
• Structure the SNT to allow gene therapy as a permitted distribution category. Include language authorizing "FDA-approved gene therapy for Rett syndrome, in consultation with the beneficiary's treating physician" as a permitted SNT distribution. This gives the trustee authority to fund an approved gene therapy without requiring a trust amendment, which can take months to complete through the court system in some states.

Special Needs Trust: structure and Rett-specific distribution language

The Special Needs Trust is the foundational financial planning tool for every Rett syndrome family. All family assets intended to benefit the daughter should flow through the SNT — not directly to her personal accounts.

Third-party SNT: for parents, grandparents, and extended family

A third-party SNT is established with family assets — parents' estate plan, grandparents' bequests, aunts' and uncles' gifts. The trust holds these assets for the daughter's benefit without counting as her countable resources for SSI or Medicaid. Third-party SNTs do not require a Medicaid payback provision; upon the daughter's death, remaining trust assets pass to her other heirs, not to the state. See the First-Party vs Third-Party SNT guide for full structural details.

First-party SNT: for direct assets received by the daughter herself

If your daughter receives assets directly in her own name — through a personal injury settlement, through an inheritance from a relative who died without an SNT in their estate plan, or through any other direct source — and those assets would disqualify her from SSI and Medicaid, a first-party (d4A) SNT can shelter them. First-party SNTs must include a Medicaid payback provision and must be established before the beneficiary turns 65. For Rett families whose daughters receive personal injury settlements, establishing the first-party SNT before any settlement funds are disbursed is critical — funds received in her name affect eligibility immediately.

Rett-specific SNT distribution language

Generic SNT language is sufficient but incomplete for Rett syndrome. Trustees benefit from explicit authorization covering the expenses most commonly needed and most likely to raise questions:

• Augmentative and alternative communication (AAC) devices. Eye-gaze communication systems (Tobii Dynavox I-Series and equivalents) typically cost $5,000–$15,000 for the hardware, plus $500–$2,000 per year in software subscriptions and updates. Devices require replacement every 3–5 years. Medicaid covers AAC devices as durable medical equipment in most states but routinely denies upgrades to newer models. SNT language should explicitly authorize AAC device purchase, mounting hardware, software licensing, and repair or replacement upon recommendation of the speech-language pathologist.
• Music therapy. Extensive research documents the benefits of music therapy for Rett syndrome — reduced stereotyped hand movements, improved emotional engagement, and decreased seizure frequency in some cases. Medicaid does not routinely cover music therapy. Explicit SNT authorization avoids trustee hesitation about whether this qualifies as a "supplemental need."
• Aquatherapy and hydrotherapy. Water-based therapy improves muscle tone, gait, and breathing regulation in Rett syndrome. Medicaid coverage is inconsistent; explicit authorization in the SNT eliminates uncertainty.
• Seizure medication co-pays and non-formulary AEDs. Approximately 80–90% of women with Rett develop seizures,¹ and many require polypharmacy including medications not on the Medicaid preferred drug list. SNT language should authorize seizure medication co-pays, non-formulary AEDs, and experimental seizure treatments approved by the treating neurologist.
• Scoliosis-related expenses. Approximately 50–80% of women with Rett develop scoliosis,¹ which may progress to require spinal bracing and potentially surgical correction (posterior spinal fusion) costing $50,000–$100,000+. SNT language should authorize scoliosis monitoring, spinal bracing, and surgical reserves.
• Wheelchair seating systems and positioning. Custom-fitted wheelchairs with specialized seating for Rett syndrome (addressing hypotonia, scoliosis, and hand stereotypy) cost $8,000–$25,000+ and require replacement every 3–5 years. The SNT supplements when insurance does not cover upgrades or customizations.
• Dental care under anesthesia. Bruxism (teeth grinding) is common in Rett syndrome, and routine dental cooperation is often impossible without sedation. General anesthesia for dental care is significantly more expensive than routine dental treatment; the SNT should explicitly authorize hospital-based dental care under anesthesia.
• Daybue-related costs not covered by Medicaid. While Medicaid covers Daybue, co-pays and any costs associated with the new Stix formulation or future reformulations may arise. SNT language should authorize all costs related to FDA-approved Rett syndrome treatments, including trofinetide in all formulations.
• FDA-approved gene therapy. As discussed above, include explicit authorization for FDA-approved gene therapy for Rett syndrome in consultation with the treating physician.

SNT sizing: modeling Rett syndrome scenarios

Sizing an SNT for Rett syndrome requires modeling two fundamentally different lifetime tracks: living at home with family as the primary care provider (supplemented by paid aides and HCBS waiver services), and living in a residential or group home setting with professional caregivers. The HCBS DD waiver changes the math dramatically in either scenario.

The Lifetime Care Cost Projection Calculator models year-by-year costs with inflation adjustment. The SNT Funding Calculator converts that projection into a recommended trust funding target.

Because women with Rett can live well into their 40s, 50s, and beyond with good care, a planning horizon of 50–60 years from birth is realistic. This extended horizon has two implications: first, the SNT needs to be funded with long-term compound growth in mind — holding the trust in highly liquid, low-growth assets is a structural mistake for a multi-decade trust; and second, the trustee succession chain must span multiple generations. A corporate co-trustee who will outlive the parents is an important element of the Rett syndrome SNT structure.

Communication technology: the recurring SNT cost most advisors miss

Most women with Rett syndrome are non-speaking or minimally verbal. Communication access — specifically AAC technology — is central to quality of life in a way that goes beyond most other disability categories, and it is a recurring cost that many financial plans underestimate.

Eye-gaze AAC systems allow communication by directing gaze to symbols, words, or a keyboard on a screen. Current high-quality devices (Tobii Dynavox I-Series and equivalents) typically cost $5,000–$15,000 for the hardware, plus $500–$2,000 per year in software and vocabulary updates, with replacement every 3–5 years. Medicare and Medicaid cover AAC devices as durable medical equipment in most states, but the authorization process is slow, and upgrades to newer models are routinely denied as "not medically necessary" when a device was provided years ago.

The SNT's role is to fund upgrades, accessories, mounting systems, and replacement devices that insurance delays or denies — and to act quickly when an aging device fails, so that communication access is not interrupted for the weeks or months a new insurance authorization might take. For trustees unfamiliar with AAC, explicit SNT language — "augmentative and alternative communication devices, mounting systems, software, accessories, and replacement devices, upon recommendation of the beneficiary's speech-language pathologist" — eliminates any ambiguity about whether such purchases are permitted distributions.

ABLE account for Rett syndrome

Women with Rett syndrome qualify for ABLE accounts under 2026 rules: eligibility requires disability onset before age 46, and Rett syndrome onset occurs in infancy.⁶ ABLE accounts can hold up to $100,000 without affecting SSI's $2,000 resource limit, with an annual contribution limit of $20,000 from all sources in 2026.

Because most women with Rett cannot independently manage an ABLE account, an ABLE authorized individual — typically a parent, sibling, or other trusted person — can open and manage the account on the beneficiary's behalf. ABLE authorized individual status is distinct from legal guardianship and from Social Security representative payee status; the same person can hold all three roles, but each is a separate legal designation obtained through a separate process.

For Rett syndrome, the ABLE account works best for smaller, recurring qualified disability expenses that the caregiver can manage directly without going through the SNT trustee process: therapy co-pays, AAC accessories, transportation to medical appointments, adaptive equipment under the annual limit. The SNT handles larger assets and more significant expenditures. Both accounts should be in place — the ABLE account for flexibility and direct caregiver control, the SNT for long-term supplemental support and larger reserves.

Guardianship and legal planning at age 18

Because Rett syndrome involves severe cognitive impairment and the inability to communicate verbally, the vast majority of women with Rett will need legal guardianship when they turn 18. Without a guardianship order, parents lose the legal authority to make medical, residential, and financial decisions for their daughter the moment she becomes a legal adult — even though she has never had the capacity to make those decisions independently.

Guardianship in the Rett context is almost always full guardianship of the person and of the estate, given the severity of impairment. Key timing and planning points:

• File the guardianship petition 3–6 months before her 18th birthday. Court processes vary by state but typically take 2–4 months; filing too close to the birthday risks a gap in legal authority.
• Designate successor guardians in the guardianship order. Name contingent successors — typically a sibling, trusted family member, or professional guardian — so that if the primary guardians (parents) become incapacitated or die, successor authority is in place without requiring an additional court proceeding at an already difficult time.
• Coordinate with the SNT trustee succession chain. A successor guardian who has no relationship with the SNT trustee creates coordination gaps in daily care decisions; a successor guardian who serves as co-trustee or works closely with the professional trustee enables seamless decision-making.
• Register SSA representative payee status separately. Social Security representative payee status — the authority to receive and manage SSI payments on behalf of the beneficiary — is separate from legal guardianship. SSA's own appointment process governs this; guardianship does not confer it automatically. Most parents of Rett daughters serve as both guardian and representative payee, but both roles must be formally registered.

HCBS Medicaid waiver: apply early and maintain waitlist position

Rett syndrome qualifies for HCBS developmental disability waivers in all states, which fund residential care, day programming, respite care, and supportive employment. Waitlists in many states run 5–15 years.⁷

Apply for the HCBS DD waiver as early as possible — in most states, families can place children on waiver waitlists in early childhood, well before they need the services. A slot that becomes available at age 18 or 21 — when school-based IDEA services end — is the difference between a funded placement and a crisis scramble for private residential care at $80,000–$150,000+ per year. Maintain the waitlist application actively: some states require annual renewal or status confirmation. See the HCBS Medicaid Waiver guide for state-by-state enrollment strategy and how waiver funding changes SNT sizing.

Life insurance for parents: funding the SNT

The most reliable funding mechanism for a Rett syndrome SNT is life insurance on the parents — typically a survivorship (second-to-die) policy that pays the death benefit when the second parent dies, at which point the daughter's primary care providers are gone and the SNT becomes her primary financial support. See the Life Insurance for SNT Funding guide for survivorship policy mechanics, how to calculate the coverage amount, and why the trust — not the daughter — must be named as beneficiary.

Key sizing inputs for Rett syndrome parents:

• Estimated SNT target from care scenario modeling (see table above)
• Current SNT assets already in place (savings, existing estate)
• Gap between current assets and target — this is the life insurance coverage need
• Include a scoliosis surgical reserve ($50K–$100K+) and a gene therapy contingency in the SNT target if Medicaid coverage cannot be assured

Given the long planning horizon for Rett syndrome — 50+ years from a diagnosis at age 2 — permanent life insurance (whole life or universal life) is generally more appropriate than term insurance, which may expire before the second parent dies and the SNT funding is most critically needed.

Priority actions for Rett families

1. Apply for SSI immediately upon confirmed Rett diagnosis. Bring MECP2 genetic test results and full clinical documentation. The CAL designation enables 10-day processing. SSI establishes Medicaid, which enables Daybue coverage if the treating physician prescribes it. There is no advantage to waiting.
2. Apply for the HCBS DD waiver immediately. Waitlists run years; apply now regardless of your daughter's current age. The sooner she is on the list, the sooner a slot can become available when IDEA services end at 21. See the HCBS Medicaid Waiver guide.
3. Audit every beneficiary designation and estate document. Replace any designations that name your daughter directly with designations to her Special Needs Trust. Every IRA, 401(k), life insurance policy, and payable-on-death account that names her directly will destroy her SSI and Medicaid upon your death — terminating Daybue coverage in the process. This is the most common and most preventable planning failure in Rett families. See the Retirement Accounts and Special Needs guide.
4. Establish or update a third-party SNT with Rett-specific distribution language. If your existing SNT does not explicitly authorize AAC devices, music therapy, aquatherapy, scoliosis reserves, and gene therapy distributions, update it now. Work with a special needs attorney experienced with complex medical conditions — not a generalist estate planner who may use boilerplate language that leaves these items ambiguous.
5. Fund the SNT with life insurance on both parents. Model the funding target using the care scenario table above and the SNT Funding Calculator. A survivorship policy is the most efficient mechanism for ensuring the SNT is funded at the moment it needs to be — when both parents are gone. Work with a fee-only financial advisor to size the policy correctly.
6. Open an ABLE account with yourself as authorized individual. Your daughter can have an ABLE account today managed by you as authorized individual. Use it for recurring small qualified disability expenses so that the SNT trustee process is reserved for larger distributions. Contact your state's ABLE program or the ABLE National Resource Center at ablenrc.org.
7. File for guardianship 3–6 months before her 18th birthday. Begin the guardianship process no later than her 17th birthday. Also contact SSA about representative payee status — the two processes are separate and both should be completed before her 18th birthday.
8. Work with a financial advisor who understands Rett-specific planning. The combination of Daybue's cost, the HCBS waiver's long waitlists, the gene therapy pipeline's uncertainty, and the multi-decade planning horizon creates a financial picture that requires specific experience. A generalist advisor who has never modeled Daybue coverage risk or a 50-year Rett care cost projection will not give you an adequate plan. A fee-only special needs specialist is the right match.

IRSF and Rett syndrome resources

The International Rett Syndrome Foundation (IRSF) maintains a comprehensive resource library for families, including information on benefits navigation, financial planning, and clinical trial access. IRSF's Care Map and clinical network connect families with Rett-experienced neurologists and developmental pediatricians who can provide the clinical documentation needed for SSA CAL applications and Daybue prior authorization.⁵

Sources

1. Rett Syndrome — StatPearls, NIH Bookshelf. Rett syndrome affects approximately 1 in 10,000–15,000 female live births, with an estimated 15,000–20,000 cases in the United States. Caused by mutations in the MECP2 gene on the X chromosome; de novo in the vast majority of cases. Almost exclusively affects females. Four clinical stages: Stage I (6–18 months, early stagnation); Stage II (1–4 years, rapid deterioration including loss of purposeful hand use and language regression); Stage III (plateau, may last decades); Stage IV (late motor deterioration in a subset). Seizures affect approximately 80–90% of individuals. Scoliosis affects approximately 50–80%. Breathing irregularities (hyperventilation, breath-holding, air swallowing) are defining features. Life expectancy with good care extends into the 40s, 50s, and beyond for many women. Molecular genetic testing (MECP2 sequence analysis) confirms diagnosis in approximately 80–95% of classic cases.
2. SSA — Compassionate Allowances: Complete List of Conditions. Rett Syndrome (RTT) is included on SSA's Compassionate Allowances (CAL) program. CAL conditions receive expedited SSDI/SSI processing — approval in approximately 10 days for confirmed cases with adequate documentation. Required documentation includes MECP2 molecular genetic test results and clinical documentation of Rett staging. CAL accelerates administrative review without changing eligibility criteria or benefit amounts.
3. SSA — Supplemental Security Income (SSI) Program. SSI Federal Benefit Rate: $994/month (2026). SSI resource limit: $2,000 countable assets. Substantial Gainful Activity (SGA): $1,690/month (non-blind, 2026). Section 1619(b): individuals who exceed SGA through earned income may retain Medicaid if they have a disabling condition and need Medicaid to maintain employment. SSI eligibility in most states triggers automatic Medicaid eligibility. Disabled Adult Child (DAC) benefits: child with disability onset before age 22 can receive up to 50% of parent's primary insurance amount on parent's retirement or disability, or 75% on parent's death; Medicare eligible after 24 months of SSDI entitlement.
4. Trofinetide (Daybue) — NIH Bookshelf / NCBI. FDA approved trofinetide (Daybue) March 2023 for treatment of Rett syndrome in adults and children aged 2 years and older — first FDA-approved treatment specifically for Rett syndrome. Dosing is weight-based (twice daily oral). List price at launch: approximately $375,000/year; annual cost ranges from approximately $427,000 to $1.335 million per year depending on patient weight because the recommended dose is weight-based. Daybue Stix (powder formulation for oral suspension) received FDA approval and launched Q1–Q2 2026; original liquid solution remains available. Trofinetide is a synthetic analog of glycine-proline-glutamate (GPE) that modulates inflammatory signaling in the CNS. Covered by most Medicaid programs as an FDA-approved treatment for an approved indication; private insurance coverage requires prior authorization.
5. International Rett Syndrome Foundation — Research & Clinical Pipeline. TSHA-102 (Taysha Gene Therapies): AAV9 intrathecal gene therapy with miRARE overexpression-control technology; FDA Breakthrough Therapy designation; Phase 1/2 REVEAL and ASPIRE trials completing dosing in Q2 2026; BLA submission planned; not FDA-approved as of 2026. NGN-401 (Neurogene): EXACT™ technology gene therapy; Phase 1/2 clinical evaluation; not FDA-approved as of 2026. Neither program is FDA-approved; both are investigational. IRSF maintains updated pipeline information, clinical trial access resources, and a Care Map connecting families with Rett-experienced clinicians. IRSF website: rettsyndrome.org.
6. ABLE National Resource Center — 2026 Contribution Limits and Eligibility. Annual ABLE contribution limit: $20,000 from all sources (2026). Age eligibility: disability onset before age 46, effective January 2026 (ABLE Age Adjustment Act). SSI protection: ABLE account balance up to $100,000 does not count toward SSI's $2,000 resource limit. ABLE authorized individual: a parent, guardian, or other trusted person may open and manage an ABLE account on behalf of an eligible beneficiary who cannot manage the account independently. ABLE authorized individual status is distinct from legal guardianship and SSA representative payee status. Qualified disability expenses include health and wellness, housing, education, transportation, employment training, assistive technology, and financial management.
7. Medicaid.gov — Home and Community-Based Services (HCBS). HCBS 1915(c) waivers fund home and community-based services for individuals who would otherwise require institutional care. Services covered include residential habilitation, day habilitation, respite care, personal care aides, supported employment, and environmental modifications. Eligibility for developmental disability waivers includes Rett syndrome. Waitlists for DD waivers average 5–15 years in most states; families should apply as early as possible. HCBS waiver enrollment is separate from SSI/Medicaid enrollment. States have discretion over waiver program structure, eligibility criteria, and waitlist management.

Rules verified against 2026 SSA, IRS, and ABLE standards. SSI FBR $994/month; SSI resource limit $2,000 (2026). SSDI SGA $1,690/month (non-blind, 2026). ABLE contribution limit $20,000/year; age eligibility onset before 46 (both 2026). Daybue list price approximately $375,000–$1.335 million per year depending on weight (current pricing, Accord BioPharma/Acadia Pharmaceuticals). TSHA-102 and NGN-401 are investigational gene therapies as of 2026 — neither is FDA-approved. This guide does not constitute financial, legal, tax, or insurance advice.